Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

ONCO 12.12.2024

Full Press ReleaseSEC FilingsOur ONCO Tweets

About Gravity Analytica

Recent News

  • 12.12.2024 - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Recent Filings

  • 12.17.2024 - 424B3 Prospectus [Rule 424(b)(3)]
  • 12.12.2024 - EFFECT Notice of Effectiveness
  • 12.12.2024 - 8-K Current report

Cincinnati, OH,Dec. 12, 2024(GLOBE NEWSWIRE) --Onconetix, Inc.(NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) onDecember 6, 2024indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the period endedSeptember 30, 2024(the “Form 10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).

OnDecember 10, 2024, the Company filed the Form 10-Q with theSecurities and Exchange Commission.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

AboutOnconetix, Inc.:

Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition ofProteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed byProteomedixand approved for sale in theEuropean Union(“EU”) under the In Vitro Diagnostic Regulation (“IVDR”). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate. For more information, visitwww.onconetix.com.

Contact Information:

Onconetix, Inc.201 E. Fifth Street, Suite 1900Cincinnati, OH45202Phone: (513) 620-4101

Investor Contact Information:

Onconetix Investor RelationsEmail:investors@onconetix.com

Primary Logo

Source: Onconetix, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com